Shop by goal

Popular compounds

GHK-Cu

GLP1-RC-RT

Research resources

Certificates of Analysis

Semaglutide: Metabolic Research research guide

In short: Semaglutide is a long-acting GLP-1 receptor agonist characterised in published research, with 94% homology to native human GLP-1 and a C18 fatty-diacid albumin-binding modification. GLP1-RC-SM is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. It is studied in preclinical (cell and animal) research and is supplied strictly for laboratory use, not for human or clinical use.

Not medical advice. Semaglutide is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.

Semaglutide at a glance

Compound type

Research peptide

Research category

Metabolic Research

Also known as

Semaglutide Acetate, GLP-1 Receptor Agonist

Molecular weight

4,113.58 Da

Research-grade purity

>99% HPLC

Evidence context

Preclinical / research use only

Regulatory status

Not an approved medicine. Supplied as a research compound

Last reviewed

14 August 2026

What to know first

Research emphasises receptor selectivity and half-life engineering compared with older GLP-1 analogues.

Laboratory buyers use it for validated assay work -not for personal use.

Receptor pharmacology: GLP-1R agonist activity characterised in published in-vitro and clinical pharmacology studies

31-amino-acid peptide with 94% sequence homology to native human GLP-1(7-37)

Aib8 substitution investigated for DPP-IV resistance; Arg34 substitution investigated for altered peptide stability

Details and limits sit in the sections below. Research use only.

What Semaglutide is

Semaglutide is a GLP-1 receptor agonist studied heavily for incretin biology, glucose regulation, and appetite circuits in research animals and clinical trial literature (outside our sales jurisdiction).

One-paragraph overview from our research datasheet. Still scientific, but faster to read than the full mechanism list below.

Semaglutide is a long-acting GLP-1 receptor agonist characterised in published research, with 94% homology to native human GLP-1 and a C18 fatty-diacid albumin-binding modification. GLP1-RC-SM is the New-U catalogue identifier for the analytically verified laboratory research material supplied here.

Quick takeaways

Research emphasises receptor selectivity and half-life engineering compared with older GLP-1 analogues.

Laboratory buyers use it for validated assay work -not for personal use.

Research contexts

Peer-reviewed papers discuss Semaglutide in specific lab settings. The points below reflect research questions, not health claims.

Research vs. personal use: Literature describes experiments in cells and animals. That is distinct from real-world use. Our products are for laboratory research only.

Typical study contexts

Regulatory clinical trials (for approved medicines) report weight and glycaemic endpoints in screened populations, those trials are not instructions for research-chemical handling.

Preclinical work often focuses on receptor pharmacology, food intake models, and pancreas-islet biology in animals.

Incretin pathways, food intake and glucose handling in rodent models.

Some drug-class molecules have clinical trials. Those are distinct from catalogue research use.

Receptor pharmacology: GLP-1R agonist activity characterised in published in-vitro and clinical pharmacology studies.

31-amino-acid peptide with 94% sequence homology to native human GLP-1(7-37).

Aib8 substitution investigated for DPP-IV resistance; Arg34 substitution investigated for altered peptide stability.

C18 fatty-diacid/mini-PEG modification investigated as a contributor to prolonged systemic exposure (~7-day apparent half-life).

Why Metabolic Research research matters

Metabolic-research peptides are studied for incretin-receptor pharmacology and energy-balance endpoints. The literature reports mechanisms and study endpoints, not guidance for any use.

Mechanisms (technical review)

Our datasheet lists mechanistic themes from preclinical work. These are research endpoints, not health claims.

Receptor pharmacology: GLP-1R agonist activity characterised in published in-vitro and clinical pharmacology studies

31-amino-acid peptide with 94% sequence homology to native human GLP-1(7-37)

Aib8 substitution investigated for DPP-IV resistance; Arg34 substitution investigated for altered peptide stability

C18 fatty-diacid/mini-PEG modification investigated as a contributor to prolonged systemic exposure (~7-day apparent half-life)

STEP-1 RCT (NEJM 2021, PMID 33567185), 2.4 mg arm: investigators reported −14.9% mean change from baseline in body weight at week 68

SELECT RCT (NEJM 2023, PMID 37952131): investigators reported a 20% relative reduction in major adverse cardiovascular events in the enrolled population

Lab handling & preparation

Storage: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation.. See the storage guide.

Published pharmacokinetic context: Published pharmacokinetic research reports an apparent elimination half-life of approximately 7 days (165–184 h) with steady-state exposure after 4–5 weeks of the protocol-defined weekly administration, a volume of distribution of ~12.5 L, >99% albumin binding, subcutaneous bioavailability of ~89%, oral (SNAC co-formulation) bioavailability of 0.4–1%, clearance of ~0.035 L/h and ~3% urinary excretion unchanged. Metabolism is reported as proteolytic cleavage plus fatty-acid β-oxidation with no CYP-mediated interactions.

Purity check: Use the COA reading guide and the published Semaglutide Certificate of Analysis.

Common Questions People Are Asking

What is Semaglutide in scientific research?

Semaglutide is a 31-amino-acid GLP-1 receptor agonist characterised in published receptor-pharmacology and clinical research. It is approved as a medicine in some jurisdictions under other manufacturers' brand names; the material supplied here is not that finished pharmaceutical.

What is GLP1-RC-SM?

GLP1-RC-SM is New-U's catalogue identifier for the laboratory research material offered through this research profile. It is not a medicine, a treatment, a generic pharmaceutical or a therapeutic product, it is not equivalent to any clinical or commercial product, and it is not offered for human or veterinary use.

Which receptor systems are examined in Semaglutide research?

Published work characterises agonist activity at the GLP-1 receptor across four tissue contexts: pancreatic β-cells (glucose-dependent insulin secretion), pancreatic α-cells (glucagon suppression), the gastrointestinal tract (delayed gastric emptying) and hypothalamic circuits (POMC/CART activation, AgRP/NPY inhibition in preclinical models). Structural work additionally investigates the C18 fatty-diacid albumin-binding modification and the Aib8 substitution for altered proteolytic stability.

What analytical testing accompanies GLP1-RC-SM?

Each released GLP1-RC-SM batch is tested by an independent analytical laboratory for purity by RP-HPLC area normalisation and for identity by mass spectrometry, and the result is published as a batch-linked Certificate of Analysis recording the laboratory, report number, measured purity and test date. Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Where can I view the current batch COA for GLP1-RC-SM?

The current batch certificate — laboratory, report number, measured purity and test date — is published at /coa/semaglutide, together with the testing history for the compound.

What does >99% HPLC purity mean?

It is a purity figure obtained by reversed-phase high-performance liquid chromatography using area normalisation: the target peak accounts for more than 99% of the total integrated peak area in the chromatogram for the tested sample. It is a statement about chemical purity of that sample only, and says nothing about sterility, endotoxin content, pharmaceutical equivalence or any clinical property.

What clinical trials are referenced on this page?

Five external studies of the reference medicine: STEP-1 (Wilding et al., NEJM 2021; PMID 33567185), SELECT (Lincoff et al., NEJM 2023; PMID 37952131), FLOW (Perkovic et al., NEJM 2024; DOI 10.1056/NEJMoa2403347), SOUL (McGuire et al., NEJM 2025; DOI 10.1056/NEJMoa2501006) and the structural paper by Lau et al. (J Med Chem 2015). Each reported result on this page is attributed to its study, arm and timepoint.

How is published clinical research distinguished from New-U batch testing?

They are separate bodies of evidence. Published clinical research is external work on the approved finished pharmaceutical, conducted under those studies' own protocols; it establishes nothing about the material supplied here. New-U batch testing is analytical work on the GLP1-RC-SM lot itself — RP-HPLC purity and mass-spectrometry identity — and it establishes nothing clinical. A certificate of analysis combined with an external clinical paper does not amount to clinical validation of GLP1-RC-SM.

Is GLP1-RC-SM the same as an approved branded medicine?

No. Approved branded semaglutide products are prescription, sterile finished pharmaceuticals manufactured under cGMP by their marketing authorisation holders. GLP1-RC-SM is unapproved laboratory research material supplied as a lyophilised powder. It is not equivalent to, a generic of, or a substitute for any approved product.

How is Semaglutide different from native GLP-1?

Published structural work describes 94% sequence homology with native human GLP-1(7-37) plus three engineered modifications: an Aib substitution at position 8 investigated for DPP-IV resistance, an Arg substitution at position 34, and a C18 fatty diacid attached at Lys26. The fatty acid is reported to bind albumin, which the literature attributes the extension of apparent half-life from roughly 2 minutes to approximately 7 days to.

What form is GLP1-RC-SM supplied in?

GLP1-RC-SM is supplied as a lyophilised powder in sealed vials, in sealed 10-vial research packs across the listed strengths, with a batch-linked Certificate of Analysis.

How should laboratory research material be stored?

Store the lyophilised powder in a freezer at −20 °C. If a laboratory protocol requires the material in solution, hold the resulting solution refrigerated at 1–6 °C, protected from light, and avoid repeated warming and cooling cycles, which can degrade the fatty-acid modification. Storage conditions are laboratory handling information only.

Is Semaglutide research compared head-to-head with Tirzepatide research?

One published trial, SURMOUNT-5 (NEJM 2025), was designed as a head-to-head comparison and reported a larger mean change from baseline in body weight in the tirzepatide arm than the semaglutide arm at week 72 (−20.2% vs −13.7%). Results from separate trials of the two compounds are not head-to-head comparisons and the study designs do not support treating them as such.

Is this page medical advice? Can I use Semaglutide for my health?

No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.

Where do I find Semaglutide specs, purity certificates and pricing?

Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.

Related peptide guides

Other compounds researchers often read about alongside Semaglutide.

Retatrutide - companion guide

Tirzepatide - companion guide

Cagrilintide - companion guide

Eloralintide - companion guide

Scientific sources & further reading

Primary literature and registries for Semaglutide, plus mainstream coverage of the peptide category. Research use only - not medical advice.

Databases & literature:

PubMed: peer-reviewed literature on Semaglutide

ClinicalTrials.gov: registered studies on Semaglutide

Semaglutide: Wikipedia (search)

Peptides in the news:

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Ready to order? View full product specs

Access concentration, batch info, variants, and current pricing on our shop.

Also known as: Semaglutide Acetate, GLP-1 Receptor Agonist

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research